• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双膦酸盐相关颌骨坏死的预防策略及临床意义:282例患者的回顾性研究

Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.

作者信息

Bonacina Riccardo, Mariani Umberto, Villa Francesco, Villa Alessandro

机构信息

Department of Dentistry, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy.

出版信息

J Can Dent Assoc. 2011;77:b147.

PMID:22129778
Abstract

OBJECTIVE

To describe and evaluate the effectiveness of oral and dental prevention strategies for cancer patients who were about to begin bisphosphonate (BP) intravenous therapy with zoledronate.

METHODS

Patients were divided into 2 groups according to their history with BPs: group PA (preventive approach) and group OB (observation). Group PA patients had never been previously treated with BPs, and group OB patients had already undergone therapy with BPs. All patients received a complete oral and dental examination and had a panoramic radiograph. If necessary, oral hygiene, and restorative and rehabilitation therapy were offered to patients. All patients participated in regular checkups every 6 months. Group PA patients underwent oral surgical procedures, as needed.

RESULTS

A total of 282 patients (162 women, 120 men) were included in this analysis (PA: n = 217; OB: n = 65). In group OB, 4.6% of patients presented with osteonecrosis of the jaw (ONJ) at first visit and 10.8% developed new ONJ during the 18-month follow-up period. No patients in group PA had ONJ. Anti-angiogenic therapy was associated with ONJ (p < 0.01) and patients with a higher number of zoledronate infusions were significantly more likely to develop ONJ (p < 0.01).

CONCLUSION

Although the incidence of BP-related ONJ is fairly low, it remains a painful and difficult complication to treat. An interdisciplinary preventive approach is essential to prevent and manage this condition.

摘要

目的

描述并评估针对即将开始使用唑来膦酸进行双膦酸盐(BP)静脉治疗的癌症患者的口腔和牙齿预防策略的有效性。

方法

根据患者使用BP的病史将其分为两组:PA组(预防措施组)和OB组(观察组)。PA组患者此前从未接受过BP治疗,OB组患者已经接受过BP治疗。所有患者均接受了全面的口腔和牙齿检查,并拍摄了全景X光片。必要时,为患者提供口腔卫生、修复和康复治疗。所有患者每6个月参加一次定期检查。PA组患者根据需要接受口腔外科手术。

结果

本分析共纳入282例患者(162例女性,120例男性)(PA组:n = 217;OB组:n = 65)。在OB组中,4.6%的患者初诊时出现颌骨坏死(ONJ),10.8%的患者在18个月的随访期内出现新的ONJ。PA组无患者发生ONJ。抗血管生成治疗与ONJ相关(p < 0.01),唑来膦酸输注次数较多的患者发生ONJ的可能性显著更高(p < 0.01)。

结论

尽管BP相关ONJ的发生率相当低,但它仍然是一种痛苦且难以治疗的并发症。跨学科的预防方法对于预防和管理这种情况至关重要。

相似文献

1
Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.双膦酸盐相关颌骨坏死的预防策略及临床意义:282例患者的回顾性研究
J Can Dent Assoc. 2011;77:b147.
2
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.“双膦酸盐性颌骨坏死”——双膦酸盐所致颌骨坏死的高、低风险因素
J Craniomaxillofac Surg. 2008 Mar;36(2):95-103. doi: 10.1016/j.jcms.2007.06.008. Epub 2008 Jan 30.
3
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.唑来膦酸治疗的晚期前列腺癌患者中双膦酸盐相关颌骨坏死的患病率及危险因素
Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26.
4
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.双膦酸盐治疗后癌症患者颌骨骨坏死:发病率及危险因素
J Clin Oncol. 2005 Dec 1;23(34):8580-7. doi: 10.1200/JCO.2005.02.8670.
5
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.关于口服双膦酸盐治疗的骨质疏松症患者颌骨坏死的文献综述:患病率、危险因素及临床特征
Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008.
6
Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.双膦酸盐相关颌骨骨坏死:乳腺癌患者危险因素的病例对照研究
J Clin Oncol. 2008 Oct 1;26(28):4634-8. doi: 10.1200/JCO.2008.16.2768. Epub 2008 Jun 23.
7
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.双膦酸盐类药物所致颌骨坏死(ONJ):乳腺癌和妇科恶性肿瘤患者中的发病率及危险因素
Gynecol Oncol. 2009 Mar;112(3):605-9. doi: 10.1016/j.ygyno.2008.11.029. Epub 2009 Jan 12.
8
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.颌骨骨坏死:接受双膦酸盐联合/不联合贝伐珠单抗治疗的转移性乳腺癌患者的口腔结局。
Clin Breast Cancer. 2011 Aug;11(4):252-7. doi: 10.1016/j.clbc.2011.02.001. Epub 2011 May 5.
9
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.唑来膦酸治疗的前列腺癌骨转移患者颌骨骨坏死:一项回顾性分析。
Acta Oncol. 2007;46(5):664-8. doi: 10.1080/02841860601185917.
10
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?双膦酸盐相关颌骨坏死:儿童会发生吗?
Clin Endocrinol (Oxf). 2008 Jun;68(6):863-7. doi: 10.1111/j.1365-2265.2008.03189.x. Epub 2008 Jan 21.

引用本文的文献

1
Management of Medication-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients With Pentoxifylline and Tocopherol: Case Reports.己酮可可碱和生育酚治疗多发性骨髓瘤患者颌骨药物相关性骨坏死:病例报告
Case Rep Dent. 2025 May 7;2025:2765925. doi: 10.1155/crid/2765925. eCollection 2025.
2
Bridging the gap - Establishing a dental-oncology service in a cancer centre.弥合差距 - 在癌症中心建立牙科肿瘤服务。
Support Care Cancer. 2024 Sep 28;32(10):693. doi: 10.1007/s00520-024-08872-x.
3
Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma-A Retrospective Observational Study of Northern Portuguese Population.
双膦酸盐输注治疗浆细胞骨髓瘤相关颌骨骨坏死——葡萄牙北部人群的一项回顾性观察研究
J Clin Med. 2024 May 2;13(9):2679. doi: 10.3390/jcm13092679.
4
Medication-related osteonecrosis of the jaw in cancer patients: Case series and review of the current literature.癌症患者颌骨药物相关性骨坏死:病例系列及当前文献综述
Rev Cient Odontol (Lima). 2022 Sep 28;10(3):e123. doi: 10.21142/2523-2754-1003-2022-123. eCollection 2022 Jul-Sep.
5
Pulp and periapical disease as a risk factor for osteonecrosis of the jaw: a national cohort-based study in Korea.牙髓和根尖周疾病作为颌骨坏死的危险因素:韩国一项基于全国队列的研究。
J Periodontal Implant Sci. 2024 Apr;54(2):65-74. doi: 10.5051/jpis.2300120006. Epub 2023 Jun 16.
6
The Role of Dental Practitioners in the Management of Oncology Patients: The Head and Neck Radiation Oncology Patient and the Medical Oncology Patient.牙科医生在肿瘤患者管理中的作用:头颈部放射肿瘤患者和内科肿瘤患者。
Dent J (Basel). 2023 May 17;11(5):136. doi: 10.3390/dj11050136.
7
Potential Relationship between Poor Oral Hygiene and MRONJ: An Observational Retrospective Study.口腔卫生不良与 MRONJ 之间的潜在关系:一项观察性回顾性研究。
Int J Environ Res Public Health. 2023 Apr 5;20(7):5402. doi: 10.3390/ijerph20075402.
8
MRONJ of the Mandible-From Decortication to a Complex Jaw Reconstruction Using a CAD/CAM-Guided Bilateral Scapula Flap.下颌骨 MRONJ-从骨切开术到使用 CAD/CAM 引导双侧肩胛骨皮瓣的复杂颌骨重建。
Medicina (Kaunas). 2023 Mar 9;59(3):535. doi: 10.3390/medicina59030535.
9
Interventions for managing medication-related osteonecrosis of the jaw.干预措施管理与药物相关的颌骨坏死。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3.
10
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.预防药物相关性颌骨坏死(MRONJ):意大利专家为口腔卫生师制定的立场文件。
Support Care Cancer. 2022 Aug;30(8):6429-6440. doi: 10.1007/s00520-022-06940-8. Epub 2022 Mar 16.